Kjell E Oberg

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. ncbi request reprint Neuroendocrine tumours
    Dan Granberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Cancer Chemother Biol Response Modif 22:471-83. 2005
  2. ncbi request reprint Endocrine tumours of the pancreas
    Kjell Oberg
    Department of Medical Sciences, University Hospital, 751 85 Uppsala, Sweden
    Best Pract Res Clin Gastroenterol 19:753-81. 2005
  3. ncbi request reprint Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET's)
    K Oberg
    Department of Medical Sciences, Endocrine Oncology, University Hospital, Uppsala, Sweden
    Rocz Akad Med Bialymst 50:62-8. 2005
  4. doi request reprint Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches
    Kjell Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Clin Cancer Res 19:2842-9. 2013
  5. doi request reprint Biotherapies for GEP-NETs
    Kjell Oberg
    Dept of Endocrine Oncology, University Hospital, Uppsala, Sweden Centre of Excellence Endocrine Tumors, Uppsala University, Uppsala, Sweden European Neuroendocrine Tumor Society, Berlin, Germany Electronic address
    Best Pract Res Clin Gastroenterol 26:833-41. 2012
  6. doi request reprint Neuroendocrine tumours in 2012: Insights into signalling pathways could individualize therapy
    Kjell Oberg
    Department of Endocrine Oncology, University Hospital of Uppsala, Sweden
    Nat Rev Endocrinol 9:70-2. 2013
  7. doi request reprint The genetics of neuroendocrine tumors
    Kjell Oberg
    Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden
    Semin Oncol 40:37-44. 2013
  8. doi request reprint Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches
    Kjell Oberg
    Department of Endocrine Oncology, Uppsala University, Uppsala, Sweden
    Curr Opin Oncol 24:433-40. 2012
  9. doi request reprint The management of neuroendocrine tumours: current and future medical therapy options
    K E Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Clin Oncol (R Coll Radiol) 24:282-93. 2012
  10. ncbi request reprint Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment
    Kjell Oberg
    Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    Curr Opin Oncol 14:38-45. 2002

Detail Information

Publications122 found, 100 shown here

  1. ncbi request reprint Neuroendocrine tumours
    Dan Granberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Cancer Chemother Biol Response Modif 22:471-83. 2005
  2. ncbi request reprint Endocrine tumours of the pancreas
    Kjell Oberg
    Department of Medical Sciences, University Hospital, 751 85 Uppsala, Sweden
    Best Pract Res Clin Gastroenterol 19:753-81. 2005
    ..None of these can cure a patient with malignant disease. In future, therapy will be custom-made and based on current knowledge of tumour biology and molecular genetics...
  3. ncbi request reprint Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET's)
    K Oberg
    Department of Medical Sciences, Endocrine Oncology, University Hospital, Uppsala, Sweden
    Rocz Akad Med Bialymst 50:62-8. 2005
  4. doi request reprint Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches
    Kjell Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Clin Cancer Res 19:2842-9. 2013
    ..These observations offer the potential for new therapeutic and diagnostic advances for patients with NET...
  5. doi request reprint Biotherapies for GEP-NETs
    Kjell Oberg
    Dept of Endocrine Oncology, University Hospital, Uppsala, Sweden Centre of Excellence Endocrine Tumors, Uppsala University, Uppsala, Sweden European Neuroendocrine Tumor Society, Berlin, Germany Electronic address
    Best Pract Res Clin Gastroenterol 26:833-41. 2012
    ....
  6. doi request reprint Neuroendocrine tumours in 2012: Insights into signalling pathways could individualize therapy
    Kjell Oberg
    Department of Endocrine Oncology, University Hospital of Uppsala, Sweden
    Nat Rev Endocrinol 9:70-2. 2013
    ..Studies published in 2012 have provided insights into tumour-cell signalling that will increase our knowledge of tumour biology and molecular genetics, making it possible to personalize patient care...
  7. doi request reprint The genetics of neuroendocrine tumors
    Kjell Oberg
    Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden
    Semin Oncol 40:37-44. 2013
    ..Genome-wide screening of different types of NETs can now be performed for a reasonable price and is likely to generate new insights into the tumor biology and carcinogenesis in various subtypes of NETs...
  8. doi request reprint Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches
    Kjell Oberg
    Department of Endocrine Oncology, Uppsala University, Uppsala, Sweden
    Curr Opin Oncol 24:433-40. 2012
    ..At the same time new targeted agents have been developed for treatment of GEP-NETs and it is important discuss these new agents in relation to the classification and staging system...
  9. doi request reprint The management of neuroendocrine tumours: current and future medical therapy options
    K E Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Clin Oncol (R Coll Radiol) 24:282-93. 2012
    ..Peptide receptor radiotherapy with [90]yttrium-DOTATOC or [177]lutetium-DOTATE is also a new interesting treatment option for NETs...
  10. ncbi request reprint Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment
    Kjell Oberg
    Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    Curr Opin Oncol 14:38-45. 2002
    ..Tumor-targeted radioactive treatment based on somatostatin analogues is now under clinical evaluation. Preliminary data indicate interesting clinical potentials...
  11. doi request reprint Pancreatic endocrine tumors
    Kjell Oberg
    Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    Semin Oncol 37:594-618. 2010
    ..In the future, treatment will be based on tumor biology and molecular genetics with the aim of so-called personalized medicine...
  12. ncbi request reprint Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors)
    Kjell Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Curr Opin Endocrinol Diabetes Obes 16:72-8. 2009
    ..However, the WHO classification introduced in clinical practice will give more insight into genetic and molecular changes related to tumor subtypes...
  13. doi request reprint Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy
    Kjell E Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Gastroenterology 139:742-53, 753.e1. 2010
    ....
  14. doi request reprint Current knowledge on diagnosis and staging of neuroendocrine tumors
    Kjell Oberg
    Department of Endocrine Oncology, Uppsala University Hospital, Akademiska sjukhuset, 751 85, Uppsala, Sweden
    Cancer Metastasis Rev 30:3-7. 2011
    ..Molecular imaging will increase in importance in the near future. There is still an unmet need for more sensitive biomarkers for diagnosis and follow-up...
  15. ncbi request reprint Interferon in the management of neuroendocrine GEP-tumors: a review
    K Oberg
    Endocrine Oncology Unit, and Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    Digestion 62:92-7. 2000
    ..It might also be possible to give higher doses of alpha interferon with hopefully improved clinical efficacy...
  16. ncbi request reprint Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
    K Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Ann Oncol 15:966-73. 2004
    ..We compare the efficacy of octreotide and lanreotide in reducing diarrhea and flushing. Side-effects are described and we provide practical information on somatostatin analog treatment...
  17. ncbi request reprint Future aspects of somatostatin-receptor-mediated therapy
    Kjell Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Neuroendocrinology 80:57-61. 2004
    ....
  18. ncbi request reprint Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview
    Kjell Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Acta Oncol 43:617-25. 2004
    ..Part I of these guidelines discusses the principles of histopathology, biochemical and radiological diagnosis as well as therapeutic options...
  19. ncbi request reprint Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types
    Kjell Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Acta Oncol 43:626-36. 2004
    ..We have, however, tried to give more updated information about the epidemiology and histopathology, which is essential for the clinical management of these tumours...
  20. ncbi request reprint Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours
    Kjell Oberg
    Department of Endocrine Oncology, University Hospital, SE 751 85, Uppsala, Sweden
    Best Pract Res Clin Endocrinol Metab 19:265-76. 2005
    ..177)Lutetium may be more effective for smaller tumours whereas (90)yttrium may be more effective for larger tumours...
  21. ncbi request reprint Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment
    Kjell Oberg
    Department of Endocrine Oncology, Uppsala University, Sweden
    Curr Opin Oncol 17:386-91. 2005
    ..Neuroendocrine tumors of the gastrointestinal tract represent a small area within oncology, but many new data have been reported during the past year. This paper updates the recent findings...
  22. ncbi request reprint Chemotherapy and biotherapy in the treatment of neuroendocrine tumours
    K Oberg
    Department of Endocrine Oncology, Medical Sciences, Internal Medicine, Uppsala University Hospital, Sweden
    Ann Oncol 12:S111-4. 2001
    ..The quality of life has been significantly improved by using the long-acting formulations...
  23. ncbi request reprint Malignant gastric ghrelinoma with hyperghrelinemia
    Apostolos V Tsolakis
    Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University Hospital, 751 85 Uppsala, Sweden
    J Clin Endocrinol Metab 89:3739-44. 2004
    ..This might be a new tumor entity of the stomach, and it is suggested that patients with malignant gastric neuroendocrine tumors should be investigated for ghrelin production...
  24. doi request reprint Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors
    Marie Louise H Fjallskog
    Department of Oncology, Uppsala University, Uppsala, Sweden
    Neuroendocrinology 88:53-8. 2008
    ..Treatment with combined streptozotocin and liposomal doxorubicin is safe and efficient in patients with endocrine pancreatic tumors (EPTs). No cardiac toxicity was reported...
  25. ncbi request reprint Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors
    B Eriksson
    Department of Internal Medicine, Uppsala University, University Hospital, Sweden
    Acta Oncol 32:189-96. 1993
    ....
  26. ncbi request reprint Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs
    H Imam
    Department of Medicine, University Hospital, Uppsala, Sweden
    Acta Oncol 36:607-14. 1997
    ..We also found that an increase in AI during high-dose somatostatin analog treatment was correlated with the biochemical response, but not with the tumor size as detected by CT in patients or with the tumor mass in the experimental model...
  27. ncbi request reprint Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography
    A Sundin
    PET Centre, and Department of Diagnostic Radiology, Uppsala University, Sweden
    Nucl Med Biol 27:33-41. 2000
    ..By utilizing data from PET scanning with both tracers, we could quantify the decarboxylation rate and tissue accumulation of [11C]-serotonin and hence the enzymatic action of aromatic amino acid decarboxylase...
  28. ncbi request reprint Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors
    E T Janson
    Department of Medical Sciences, University Hospital, Uppsala, Sweden
    Nucl Med Biol 26:877-82. 1999
    ....
  29. ncbi request reprint High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours
    Staffan V Welin
    Department of Medical Sciences, University Hospital, Uppsala, Sweden
    Eur J Endocrinol 151:107-12. 2004
    ..To explore this therapeutic strategy further, we have studied the effect of a high-dose formula of octreotide, octreotide pamoate, in midgut carcinoid patients...
  30. ncbi request reprint Interferon alpha induction of Stat1 and Stat2 and their prognostic significance in carcinoid tumors
    Y Zhou
    Endocrine Oncology Unit of Internal Medicine, Uppsala University Hospital, Uppsala, Sweden
    Oncology 60:330-8. 2001
    ..Thus, the antitumor effect, in vivo and in vitro, in IFN-alpha-treated carcinoid tumors seems to be mediated via upregulation of Stat proteins and enhancement of phosphorylation of these proteins...
  31. ncbi request reprint Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies
    E T Janson
    Department of Internal Medicine, University Hospital, Uppsala, Sweden
    Cancer Res 58:2375-8. 1998
    ..Thus, these antibodies may be used to determine the presence of sst2 in carcinoid tumors and to select patients suitable for somatostatin analogue treatment. The method is easily applicable in clinical practice...
  32. ncbi request reprint An update of the medical treatment of malignant endocrine pancreatic tumors
    B Eriksson
    Medical Department, University Hospital, Uppsala, Sweden
    Acta Oncol 32:203-8. 1993
    ..In conclusion, there are at least three effective therapies for malignant EPT and by combining them simultaneously or consecutively, a median survival of more than four years can be obtained...
  33. ncbi request reprint In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex
    A Lukinius
    Department of Genetics and Pathology, University Hospital, Uppsala, Sweden
    Acta Oncol 38:383-7. 1999
    ..However, the importance of the number of somatostatin receptors and subtypes expressed will have to be further studied...
  34. ncbi request reprint Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin
    M Afargan
    Departments of Medicinal Sciences and Endocrine Oncology, University Hospital SE 75185, Uppsala, Sweden
    Endocrinology 142:477-86. 2001
    ..These results suggest that PTR-3173 is the first highly selective somatostatinergic analog for the in vivo inhibition of GH secretion, with minimal or no effect on glucagon and insulin release, respectively...
  35. ncbi request reprint Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors
    D Granberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Acta Radiol 48:180-5. 2007
    ..To report our experience of liver embolization with trisacryl gelatin microspheres (Embospheretrade mark) in patients with metastatic neuroendocrine tumors...
  36. ncbi request reprint Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs
    M L Fjällskog
    Department of Medical Sciences, University Hospital, Uppsala, Sweden
    Med Oncol 19:35-42. 2002
    ..However, in this study, the value of sequential treatment has not been evaluated...
  37. ncbi request reprint Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography
    H Orlefors
    Department of Medical Sciences Endocrine Oncology, Uppsala University Hospital, UAS, 751 85, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 33:60-5. 2006
    ....
  38. ncbi request reprint Chromogranins--new sensitive markers for neuroendocrine tumors
    B Eriksson
    Ludwig Institute for Cancer Research, Biomedical Center, Uppsala, Sweden
    Acta Oncol 28:325-9. 1989
    ..Also in immunocytochemical stainings, our polyclonal antiserum detecting both chromogranin A and B showed a greater sensitivity than other available antisera against chromogranin A, B and C...
  39. ncbi request reprint Developments in PET for the detection of endocrine tumours
    B Eriksson
    Department of Endocrine Oncology, University Hospital, SE 751 85 Uppsala, Sweden
    Best Pract Res Clin Endocrinol Metab 19:311-24. 2005
    ..Development of new PET radiopharmaceuticals may in the future allow in vivo detection of tumour biological properties, such as malignant potential and responsiveness to treatment...
  40. ncbi request reprint Demonstration of high monoaminoxidase-A levels in neuroendocrine gastroenteropancreatic tumors in vitro and in vivo-tumor visualization using positron emission tomography with 11C-harmine
    H Orlefors
    Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    Nucl Med Biol 30:669-79. 2003
    ..The aim of this study was to investigate some of the monoamine processing pathways of neuroendocrine GEP-tumors and try to find a new tracer substance for in vivo characterization and visualization by Positron Emission Tomography (PET)...
  41. ncbi request reprint Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide
    J E Westlin
    Department of Oncology, University Hospital, Uppsala, Sweden
    Acta Oncol 32:783-6. 1993
    ..Two of these lesions represented previously undetectable primary tumours. It is concluded that somatostatin receptor scintigraphy using [111In-DTPA-D-Phe1]-octreotide has a future role in the staging of patients with carcinoid disease...
  42. ncbi request reprint Medical treatment of neuroendocrine gut and pancreatic tumors
    K Oberg
    Ludwig Institute for Cancer Research, University Hospital, Uppsala, Sweden
    Acta Oncol 28:425-31. 1989
    ..The somatostatin analogue has proved to be particularly useful in the treatment of patients with severe hormone-related clinical symptoms and in the perioperative period.(ABSTRACT TRUNCATED AT 400 WORDS)..
  43. ncbi request reprint Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin--alone or in combination with 5-FU
    K Oberg
    Ludwig Institute for Cancer Research, Uppsala Branch, University Hospital, Sweden
    Acta Oncol 26:429-32. 1987
    ..Our data indicate that combination treatment with streptozocin and 5-fluorouracil is of little value for patients with malignant carcinoid tumors...
  44. ncbi request reprint Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors
    B Eriksson
    Medical Department, University Hospital, Uppsala, Sweden
    Acta Oncol 30:477-83. 1991
    ..Recent findings might indicate that CA-50 could be an indicator of malignant disease and possibly also correlate with survival...
  45. ncbi request reprint Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon
    E T Janson
    Department of Internal Medicine, University Hospital, Uppsala, Sweden
    Acta Oncol 32:225-9. 1993
    ..Our results also indicate that the combination of octreotide and alpha-interferon might be of beneficial value for long-term management of this disease...
  46. ncbi request reprint Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography
    H Orlefors
    Department of Medical Sciences Endocrine Oncology, Uppsala University Hospital, S 751 85 Uppsala, Sweden
    J Clin Endocrinol Metab 90:3392-400. 2005
    ..This study also shows that WB-(11)C-HTP-PET is sensitive in imaging small NET lesions, such as primary tumors, and can in a majority of cases image significantly more tumor lesions than SRS and CT...
  47. ncbi request reprint Differentially expressed cDNAs in PLCbeta3-induced tumor suppression in a human endocrine pancreatic tumor cell line: activation of the human mismatch repair protein 3 gene
    P Stalberg
    Endocrine Oncology Unit, Department of Medical Sciences, University Hospital, Uppsala, 751 85, Sweden
    Biochem Biophys Res Commun 281:227-31. 2001
    ..Differential expression of these genes may contribute to the PLCB3-induced tumor suppression of neuroendocrine tumor cell lines...
  48. ncbi request reprint Experience in treatment of metastatic pulmonary carcinoid tumors
    D Granberg
    Department of Medicine, University Hospital, Uppsala, Sweden
    Ann Oncol 12:1383-91. 2001
    ..In the present paper, we report the results of medical treatment of patients with metastatic tumors, their circulating hormone markers, and immunohistochemical profile of the tumors...
  49. ncbi request reprint Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook
    B Eriksson
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Ann Oncol 10:S31-8. 1999
    ..g., inhibition of exocytosis, antiproliferative effects and induction of apoptosis during treatment will help to optimize treatment and provide new insights into mechanisms of action of somatostatin analogs...
  50. ncbi request reprint Established clinical use of octreotide and lanreotide in oncology
    K Oberg
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Chemotherapy 47:40-53. 2001
    ..Tumor-targeted therapy with (111)In and (90)Y coupled to somatostatin analogs show promising results but await further studies...
  51. ncbi request reprint Tumor markers in neuroendocrine tumors
    B Eriksson
    Section for Endocrine Oncology, Department of Medical Sciences, University Hospital, Uppsala, Sweden
    Digestion 62:33-8. 2000
    ..Chromogranin A serum or plasma levels reflect tumor load, and it may be an independent marker of prognosis in patients with midgut carcinoids...
  52. ncbi request reprint Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies
    B Eriksson
    Department of Medical Sciences, Uppsala University PET Centre, Sweden
    Q J Nucl Med 44:68-76. 2000
    ..It detects more lesions in the liver and lymph nodes than other methods and furthermore, it can be used to monitor treatment effects...
  53. ncbi request reprint Somatostatin induces rapid contraction of neuroendocrine cells
    Jan Saras
    Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden
    FEBS Lett 581:1957-62. 2007
    ..It is therefore concluded that the inhibitory effect of somatostatin in forskolin-stimulated cells is not dependent on cell contraction...
  54. doi request reprint Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up
    K Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Ann Oncol 19:ii104-5. 2008
  55. ncbi request reprint Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients
    B Eriksson
    Ludwig Institute for Cancer Research, University Hospital, Uppsala, Sweden
    Acta Oncol 28:373-7. 1989
    ..1 versus 5.8 years). Patients who received interferon after failing chemotherapy had a significantly better survival than those given chemotherapy alone (5-year survival 65 and 50% respectively)...
  56. ncbi request reprint In vitro culture of neuroendocrine tumors of the pancreas and gut
    M Lundqvist
    Ludwig Institute for Cancer Research, University Hospital, Uppsala, Sweden
    Acta Oncol 28:335-9. 1989
    ..This observation correlated to positive immunostaining to chromogranin A and synaptophysin. Different growth factors might stimulate different fractions of tumor cells to retain the endocrine characteristics...
  57. ncbi request reprint Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial
    E T Janson
    Department of Internal Medicine, University Hospital, Uppsala, Sweden
    Acta Oncol 32:231-3. 1993
    ..Other adverse reactions were skin lesions and myalgia. The combination therapy demonstrated subjective improvement in half of the patients, but lacked antitumoral effects...
  58. ncbi request reprint Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1
    M Essand
    Division of Clinical Immunology, Uppsala University, Sweden
    J Mol Endocrinol 35:489-501. 2005
    ..Furthermore, while VMAT1 can take up serotonin, VMAT1Delta15 cannot, indicating different functions for the two forms of VMAT1...
  59. ncbi request reprint A comparison between three commercial kits for chromogranin A measurements
    M Stridsberg
    Department of Medical Sciences, Clinical Chemistry, Uppsala University Hospital, S 751 85 Uppsala, Sweden
    J Endocrinol 177:337-41. 2003
    ..A recognised international standard for CgA would be a step on the way to harmonisation, but antibody selection and construction of the assays will probably still influence the results...
  60. ncbi request reprint Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effects
    E Tiensuu Janson
    Department of Medical Sciences, University Hospital, Uppsala, Sweden
    Acta Oncol 38:373-7. 1999
    ..We conclude that treatment with [(111)In-DTPA-D-Phe1]-octreotide can be used in patients with neuroendocrine tumors but blood parameters have to be carefully monitored to avoid severe side effects...
  61. ncbi request reprint Management of neuroendocrine tumours
    K Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Ann Oncol 15:iv293-8. 2004
  62. ncbi request reprint Decreased survival in patients with CD44-negative typical bronchial carcinoid tumors
    D Granberg
    Department of Medicine, University Hospital, Uppsala, Sweden
    Int J Cancer 84:484-88. 1999
    ..However, positive staining for CD44s, v7-8 and v9 seems to be associated with a more favorable outcome, and may be taken into consideration in prognostic evaluation...
  63. ncbi request reprint Three-dimensional OctreoScan111 SPECT of abdominal manifestation of neuroendocrine tumours
    J E Westlin
    Department of Oncology, University Hospital, Uppsala, Sweden
    Acta Oncol 32:171-6. 1993
    ....
  64. ncbi request reprint Nuclear DNA distribution in neuroendocrine gastroenteropancreatic tumors before and during treatment
    B Eriksson
    Ludwig Institute for Cancer Research, Uppsala, Sweden
    Acta Oncol 28:193-7. 1989
    ..A change from diploid to aneuploid records was also seen in 7/23 (30%) carcinoid tumors after treatment. The DNA patterns before and after treatment did not show any correlation with survival or treatment response...
  65. ncbi request reprint Molecular cloning and characterization of a cDNA encoding mouse phospholipase C-beta3
    S Wang
    Department of Internal Medicine, Uppsala University Hospital, S 751 85 Uppsala, Sweden
    Biochim Biophys Acta 1393:173-8. 1998
    ..The observation of PLC-beta3 nuclear localization suggests that PLC-beta3 may have intranuclear functions...
  66. pmc Interferons in the management of neuroendocrine tumors and their possible mechanism of action
    K Oberg
    Department of Internal Medicine and Ludwig Institute for Cancer Research, University Hospital, Uppsala, Sweden
    Yale J Biol Med 65:519-29; discussion 531-6. 1992
    ..The adverse reactions are dose-dependent and manageable. The anti-tumor effects of alpha interferons are pleiotropic and include several direct effects on tumor cells but also immunomodulation...
  67. ncbi request reprint Prognostic markers in patients with typical bronchial carcinoid tumors
    D Granberg
    Department of Medicine, University Hospital, Uppsala, Sweden
    J Clin Endocrinol Metab 85:3425-30. 2000
    ..Moreover, CD44, nm23, and Ki-67 may give valuable prognostic information and help identify the patients at risk of disease-related death...
  68. ncbi request reprint Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors
    Marie Louise H Fjallskog
    Department of Medical Sciences, University Hospital, SE 751 85 Uppsala, Sweden
    Clin Cancer Res 9:1469-73. 2003
    ..We have examined the expression of molecular targets in patients with malignant endocrine pancreatic tumors, which is necessary to justify additional studies investigating the potential benefit from such treatment...
  69. ncbi request reprint Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues
    E Ludvigsen
    Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden
    Regul Pept 138:1-9. 2007
    ..For insulin and glucagon, combinations of sst2+sst5 and sst1+sst2, respectively may exert this effects. Thus, our data suggest that more than one sst must be involved to down-regulate islet glucagon and insulin secretion...
  70. ncbi request reprint Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours
    G Larsson
    Department of Public Health and Caring Sciences, Uppsala University, Sweden
    Acta Oncol 40:825-31. 2001
    ..Thus, deterioration of physical function was not accompanied by a deterioration of emotional function, and levels of tumour markers were not related to patients' HRQoL...
  71. ncbi request reprint Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism
    A E Gobl
    Department of Medical Sciences, Endocrine Oncology Unit, Uppsala University Hospital, S 751 85, Uppsala, Sweden
    Biochim Biophys Acta 1447:51-6. 1999
    ..This would result in loss of repression of menin/JunD target genes, as well as non-target genes through indirect mechanisms, deregulation of cellular growth control and endocrine tumorigenesis...
  72. ncbi request reprint Somatostatin receptor ligands and their use in the treatment of endocrine disorders
    E T Janson
    Dept of Medical Sciences, Section of Endocrine Oncology, University Hopsital, Uppsala, S 751 85 Uppsala, Sweden
    Curr Pharm Des 5:693-705. 1999
    ..These new somatostatin receptor subtype specific analogues will soon be tested in clinical trials. In this review article the development of new analogues and new preparations of old analogues and their use in the clinic is discussed...
  73. ncbi request reprint Targeted disruption of the mouse phospholipase C beta3 gene results in early embryonic lethality
    S Wang
    Department of Internal Medicine, University Hospital, Uppsala, Sweden
    FEBS Lett 441:261-5. 1998
    ..We also showed that mouse PLCbeta3 is expressed in unfertilized eggs, 3-cell and egg cylinder stages of embryos. In conclusion, these results indicate that PLCbeta3 expression is essential for early mouse embryonic development...
  74. ncbi request reprint The ultimate biochemical diagnosis of endocrine pancreatic tumours in MEN-1
    K Oberg
    Department of Internal Medicine, University Hospital, Uppsala, Sweden
    J Intern Med 243:471-6. 1998
    ....
  75. pmc Expression and prognostic significance of Bcl-2 in ovarian tumours
    R Henriksen
    Department of Gynecology and Obstetrics, University Hospital, Uppsala, Sweden
    Br J Cancer 72:1324-9. 1995
    ..Our results indicate an inhibitory role of bcl-2 in development and progression of ovarian tumours...
  76. ncbi request reprint Interferon treatment of neuroendocrine tumour xenografts as monitored by MRI
    A Elvin
    Department of Diagnostic Radiology, University Hospital, Uppsala, Sweden
    Acta Oncol 33:567-71. 1994
    ..The animal model was probably unsuitable for demonstration of IFN effects...
  77. ncbi request reprint Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide
    K Oberg
    Ludwig Institute for Cancer Research, Department of Internal Medicine, University Hospital, Uppsala, Sweden
    Acta Oncol 30:503-7. 1991
    ..The somatostatin analogue SMS 201-995 has a beneficial effect in the treatment of patients with the carcinoid syndrome. However, the precise role of the drug in the long-term management of these patients has to be further investigated...
  78. ncbi request reprint Assignment of the mouse homologue of a human MEN1 candidate gene, phospholipase C-beta 3 (Plcb3), to chromosome region 19B by FISH
    A E Gobl
    Department of Internal Medicine, University Hospital, Uppsala, Sweden
    Cytogenet Cell Genet 71:257-9. 1995
    ..This is in agreement with the comparative mapping of the MEN1 flanking markers in mouse...
  79. ncbi request reprint Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours
    G Larsson
    Department of Medicine, Uppsala University, Sweden
    Ann Oncol 10:1321-7. 1999
    ..Little is known about the health-related-quality of life (HRQoL) of patients with endocrine gastrointestinal tumours. In this study, HRQoL was investigated in long-term survivors of endocrine GI tumours...
  80. doi request reprint Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up
    K Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Ann Oncol 19:ii102-3. 2008
  81. ncbi request reprint Genetic and clinical characteristics of multiple endocrine neoplasia type 1
    B Skogseid
    Department of Internal Medicine, University Hospital, Ludwig Institute for Cancer Research, Uppsala, Sweden
    Acta Oncol 30:485-8. 1991
    ..Although it still remains to be established whether early intervention will have an impact on mortality, our long-term experience with 20 MEN 1 kindreds suggests a reduced morbidity as a result of thorough biochemical screening...
  82. ncbi request reprint Multiple endocrine neoplasia type 1 (MEN-1). Clinical, biochemical and genetical investigations
    K Oberg
    Ludwig Institute for Cancer Research, University Hospital, Uppsala, Sweden
    Acta Oncol 28:383-7. 1989
    ..The causative medical treatment of patients with malignant endocrine pancreatic tumors and the MEN-1 trait include chemotherapy (streptozotocin plus 5-fluorouracil), interferons and the somatostatin analogue SMS 201-995...
  83. ncbi request reprint Molecular cloning and characterization of a cDNA encoding the rat interleukin-8 receptor
    A E Gobl
    Department of Internal Medicine, University Hospital, Uppsala, Sweden
    Biochim Biophys Acta 1326:171-7. 1997
    ..IL-8R mRNA containing cells were predominately found in the mantle zone of the germinal center. These cells were identified as B lymphocytes using the OX-33 monoclonal antibody...
  84. ncbi request reprint Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona 08035, Spain
    Endocr Relat Cancer 14:221-32. 2007
    ..Also a comprehensive review of the literature about chemotherapy in NETs is presented...
  85. ncbi request reprint Effects of interferon alpha on the expression of p21cip1/waf1 and cell cycle distribution in carcinoid tumors
    Yinghua Zhou
    Department of Medical Sciences, Endocrine Oncology Unit of Internal Medicine, Uppsala University Hospital, S751 85 Uppsala, Sweden
    Cancer Invest 20:348-56. 2002
    ..Based on these results, we conclude that IFN-alpha exerts antitumor effects by increased p21 expression in neuroendocrine tumors...
  86. ncbi request reprint A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy
    Justyna Leja
    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Clin Cancer Res 13:2455-62. 2007
    ..We therefore constructed Ad[CgA-E1A], a novel replication-selective oncolytic adenovirus, where the chromogranin A (CgA) promoter controls expression of the adenoviral E1A gene...
  87. ncbi request reprint Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases
    Per Hellman
    Department of Surgery, University Hospital, SE 751 85 Uppsala, Sweden
    World J Surg 26:991-7. 2002
    ..Liver metastases and significant preoperative weight loss are identified as major negative prognostic factors for survival...
  88. ncbi request reprint Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
    Sara Ekeblad
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Clin Cancer Res 13:2986-91. 2007
    ..A retrospective analysis of the toxicity and efficacy of temozolomide in advanced neuroendocrine tumors...
  89. ncbi request reprint Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years
    Henrik Kindmark
    Department of Medicine Endocrine Oncology, University Hospital, Uppsala, Sweden
    Med Oncol 24:330-7. 2007
    ..In an attempt to assess the efficacy of diagnostic and therapeutic measures in patients with glucagonoma, a retrospective study was performed using the archives of a tertiary care center...
  90. doi request reprint Gastroenteropancreatic neuroendocrine tumours
    Irvin M Modlin
    Department of Gastroenterological Surgery, Yale University, New Haven, CT 06520 8062, USA
    Lancet Oncol 9:61-72. 2008
    ..Progress is unlikely to occur without development of centers of excellence, with dedicated combined clinical teams to coordinate multicentre studies, maintain clinical and tissue databases, and refine molecularly targeted therapeutics...
  91. doi request reprint Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report
    Dan Granberg
    Department of Endocrine Oncology, Faculty of Medicine, University of Uppsala, University Hospital, Uppsala, Sweden
    Digestion 77:92-5. 2008
    ..In patients with metastatic gastrinomas not suitable for chemotherapy, interferon or targeted radiotherapy, single therapy with somatostatin analogs may be an alternative...
  92. doi request reprint Selective internal radiation therapy in patients with carcinoid liver metastases
    Dan Granberg
    Acta Oncol 47:1169-71. 2008
  93. ncbi request reprint Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET)
    Hendricks H Whitman
    Summit Medical Group, One Diamond Hill Road, Berkeley Heights, NJ 07922, USA
    Ann N Y Acad Sci 1073:59-78. 2006
    ..If pheochromocytoma is ruled out, yet symptoms and biochemical markers for catecholamine excess are present, then carcinoid and other amine-precursor-uptake decarboxylation (APUD) tumors must remain in the differential diagnosis...
  94. ncbi request reprint [Lung carcinoids--not so benign as earlier believed]
    Dan Granberg
    Akademiska sjukhuset, Uppsala
    Lakartidningen 103:2382-4. 2006
  95. ncbi request reprint Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment
    E Tiensuu Janson
    Department of Medical Sciences, University Hospital, Uppsala, Sweden
    Cancer Chemother Biol Response Modif 21:535-46. 2003
  96. ncbi request reprint Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors
    Marie Louise Fjällskog
    Department of Medical Sciences, University Hospital, Uppsala, Sweden
    Med Oncol 20:59-67. 2003
    ..These differences indicate the importance of determining each tumor s subset of receptors before treatment with receptor-subtype-specific analogs is initiated. The importance of sst expression in intratumoral vessels is not yet known...
  97. ncbi request reprint Malignant neuroendocrine tumors
    Eva Tiensuu Janson
    Department of Medical Sciences, University Hospital, S 751 85 Uppsala, Sweden
    Cancer Chemother Biol Response Modif 20:463-70. 2002
  98. ncbi request reprint Gene expression in midgut carcinoid tumors: potential targets for immunotherapy
    Sofia Vikman
    Division of Clinical Immunology, Uppsala University, Uppsala, Sweden
    Acta Oncol 44:32-40. 2005
    ..This study elucidates that TPH1, VMAT1, and Survivin should be further investigated as potential target antigens for T cell-mediated immunotherapy of midgut carcinoids...
  99. ncbi request reprint Diagnosis and treatment of carcinoid tumors
    Kjell Oberg
    Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
    Expert Rev Anticancer Ther 3:863-77. 2003
    ..New therapies, such as antiangiogenic agents and new, long-acting somatostatin analogs, together with further development of tumor-targeted treatments, will come into clinical use in the near future...
  100. ncbi request reprint A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A
    Mats Stridsberg
    Department of Medical Sciences, Clinical Chemistry, Uppsala University Hospital, S 751 85, Uppsala, Sweden
    Regul Pept 117:219-27. 2004
    ..Several CgA-related peptides have been identified in tissue, and many of the biological effects attributed to CgA seem to be mediated by these peptides...
  101. ncbi request reprint Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors
    Nicola Fazio
    J Clin Oncol 22:573-4; author reply 574-5. 2004